Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer
December 6, 2021
Ryan Allway December 6th, 2021 Psychedelics, Top News NAPLES, Fla., Dec. 6, 2021 /PRNewswire/ — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced the appointment of Bob Dagher, MD,... Read more
Cognetivity Neurosciences Partners with Ketamine One in Collaborative Clinical Study on Depression and PTSD
December 2, 2021
Ryan Allway December 2nd, 2021 Psychedelics Research study follows deployment of Cognetivity’s ICA in Ketamine One’s North American clinics and will open up novel, tailored use cases in burgeoning mental health market VANCOUVER, BC, Dec. 2, 2021 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity“) (CSE: CGN) (OTCQB: CGNSF) (FWB:... Read more
Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
Biotechnology November 24, 2021
Ryan Allway November 24th, 2021 Psychedelics MIAMI BEACH, Fla., Nov. 24, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that it has... Read more
Clearmind Medicine Launches Study for Binge Eating with The Hebrew University Using its Proprietary MEAI Compound
November 24, 2021
Ryan Allway November 24th, 2021 Psychedelics Focus on the discovery and development of novel therapeutic strategies to treat obesity and its related metabolic disorders TORONTO, Nov. 24, 2021 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF), (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on... Read more
Ryan Allway November 24th, 2021 Psychedelics Shipment of GMP DMT, In Vitro HERG and Genotox Assays Completed, and In Vivo Toxicity Assays Underway Vancouver, British Columbia–(November 24, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic... Read more
VANCOUVER, British Columbia–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to formally announce the opening of its seventh psychedelic assisted psychotherapy (“PAP”) clinic located at 42450 Twelve Mile Road, Novi, Michigan, 48377. “Revitalist is providing Novi access to much needed services... Read more
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities
New York November 23, 2021
Ryan Allway November 23rd, 2021 Psychedelics TORONTO–(BUSINESS WIRE)-11/23/2021- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced it has awarded a grant for the first psychedelic treatment clinic at Lenox Hill Hospital, part of Northwell Health, to serve marginalized and... Read more
Ryan Allway November 18th, 2021 Psychedelics MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics VANCOUVER, BC, Nov. 18, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS... Read more
Clearmind Medicine Engages Bar-Ilan University to Evaluate Anti-Addictive Properties of Clearmind’s Proprietary MEAI Compound
November 18, 2021
Ryan Allway November 18th, 2021 Psychedelics Professor Gal Yadid, renowned neuropsychopharmacologist, to spearhead the project Toronto, Ontario–(Newsfile Corp. – November 18, 2021) – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC Pink: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived... Read more
MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease
November 16, 2021
Ryan Allway November 16th, 2021 Psychedelics The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer’s Disease diagnostics VANCOUVER, BC, Nov. 16, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS... Read more
